Synchron, Inc. develops endovascular brain-computer interfaces that enable paralyzed patients to control digital devices through thought alone. Founded in 2012 and headquartered in Brooklyn, the company has pioneered a minimally invasive approach to brain-computer interface technology, utilizing blood vessels to access the brain rather than requiring open surgery. This endovascular method differentiates Synchron from competitors by reducing surgical risks and potentially accelerating patient adoption. The company's flagship technology translates neural signals into digital commands, allowing patients with severe paralysis to operate computers, smartphones, and other devices directly through mental intention. Synchron has achieved significant regulatory milestones, becoming the first company to receive FDA approval for a permanently implanted brain-computer interface in human patients. The technology addresses a substantial unmet medical need for individuals with conditions such as ALS, stroke, and spinal cord injuries. Synchron continues to advance clinical development while expanding its platform capabilities to serve the growing market for neural interface solutions.